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Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) antibody testing in 
community settings may help us better understand the immune response to this virus and, therefore, 
help guide public health efforts.
Aim: To conduct a seroprevalence study of immunoglobulin G (IgG) antibodies in Irish GP clinics.
Design & setting: Participants were 172 staff and 799 patients from 15 general practices in the 
Midwest region of Ireland.
Method: This seroprevalence study utilised two manufacturers’ point- of- care (POC) SARS- CoV-2 
immunoglobulin M (IgM)—IgG combined antibody tests, which were offered to patients and staff in 
general practice from 15 June to 10 July 2020.
Results: IgG seroprevalence was 12.6% in patients attending general practice and 11.1% in staff 
working in general practice, with administrative staff having the lowest seroprevalence at 2.5% and 
nursing staff having the highest at 17.6%. Previous symptoms suggestive of COVID-19 and history of 
a polymerase chain reaction (PCR) test were associated with higher seroprevalence. IgG antibodies 
were detected in approximately 80% of participants who had a previous PCR- confirmed infection. 
Average length of time between participants’ positive PCR test and positive IgG antibody test was 
83 days.
Conclusion: Patients and healthcare staff in general practice in Ireland had relatively high rates of IgG 
to SARS- CoV-2 compared with the national average between 15 June and 10 July 2020 (1.7%). Four- 
fifths of participants with a history of confirmed COVID-19 disease still had detectable antibodies an 
average of 12 weeks post- infection. While not proof of immunity, SARS- CoV-2 POC testing can be 
used to estimate IgG seroprevalence in general practice settings.
How this fits in
The immune response to the SARS- CoV-2 virus continues to be characterised. This study examined 
for presence of IgG in 172 general practice staff and 799 patients from 15 June to 10 July 2020. While 
rates of seroprevalence were higher than estimated population- wide levels, they do not suggest 
COVID-19 has passed silently through our communities to any large degree. POC serologic studies 
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can easily be integrated into routine general practice, and may help inform seroprevalence studies 
and other public health efforts required during this pandemic.
Introduction
A novel virus, SARS- CoV-2, first detected in Wuhan, China, in December 2019,1 caused a global 
pandemic and >3.7 million deaths worldwide by 8 June 2021.2 The rapid spread of SARS- CoV-2, 
asymptomatic infection, and the requirement to understand how vaccination will impact the pandemic 
have fuelled interest in large- scale screening.3–8
The standard method for diagnosis of SARS- CoV-2 infection remains a nucleic acid real- time PCR 
test. Although these tests have low levels of false positives, they are limited by a relatively high rate 
of false- negative results owing to multiple influencing factors, including virus shedding rates and the 
technical difficulty of performing an effective nasopharyngeal swab.9 While rapid, easily deployed, 
POC testing has been employed successfully in cohorting patients with viral illness, specifically 
influenza,10 POC antigen tests to detect active SARS- CoV-2 infection in real- world settings, while 
evolving, have yet to replace PCR testing.11,12
While unlikely to impact on acute management, use of reliable POC tests for antibodies as a result 
of infection or vaccination may provide additional relevant information to public health authorities 
in their management of the pandemic.5,8 Many rapid, simple, POC lateral flow immunoassay (LFIA) 
tests to simultaneously detect IgM and IgG antibodies against SARS- CoV-2 in human blood within 15 
minutes have been developed.13,14 Performance characteristics of these tests vary, although a majority 
have sensitivities of >80% when used after day 15 of infection.15–17 If this lag between infection and 
detectable antibody levels17–19 is accounted for, POC antibody tests can help identify who has been 
previously infected.17,20 How long such antibodies will persist is unclear, although studies thus far have 
confirmed their presence for at least 6 months.21–24
Much is still unknown about the immune response to COVID-19, such as whether antibodies created 
in response to infection or vaccination confer protection from severe disease, from reinfection, or for 
how long protection might be sustained.23–28 Reinfections, potentially by genomically different virus 
strains,29,30 are also a source of concern, as are new variant strains with increased transmissibility.31
Natural active immunity from previous infection seems to prevent reinfection in approximately 
80% of cases (although this figure is lower for older patients),29 but the role IgG antibodies play is 
not well defined. It appears upwards of 80% of those infected by SARS- CoV-2 make IgG antibodies 
in response25,26 and this group continues to make IgG antibodies for >6 months,23,27 which is a figure 
that is being revised upwards as time passes. Titres do drop over time but numbers of memory B 
cells27 and the proportion of those with detectable antibodies seem to remain stable.23 However, the 
immune response is complex, involving memory B cells, antibodies, memory CD4+ T cells, and/or 
memory CD8+ T cells. Thus, it seems simple serological tests for SARS- CoV-2 antibodies may never 
adequately describe the 'richness and durability' of immune memory to COVID-19.24 Nevertheless, 
at population level, these tests may assist seroprevalence studies and assessment of those with long- 
term clinical sequelae.28
Therefore, well- designed studies, with clear reporting of time lag between diagnosed infections 
and antibody detection,17 to elucidate the mechanisms and serological correlates of protective 
immunity, may help guide rational clinical and public health policies.
As there is limited published information on the deployment of antibody POC tests in primary 
care settings, and none, to the authors’ knowledge, in the Irish population, the aim was to conduct a 
seroprevalence study among patients and healthcare workers in general practice in Ireland for SARS- 
CoV-2 using combined IgM–IgG antibody POC tests.
Method
General practices of the University of Limerick Education and Research Network for General Practice 
(ULEARN- GP)32 were invited to participate by email and follow- up phone call. This network comprises 
134 practices in Ireland, centred around the Midwest. Acquisition of 1000 POC testing kits from two 
manufacturers determined the number of practices that could be approached as it was intended to 
offer kits to practices in batches of 25–50. A selection of small and large practices from villages, towns, 
and cities in the Midwest were emailed an invitation to participate in the study. If an invited practice 
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declined to participate, the next similar practice in the network was chosen until all POC tests were 
distributed. Details of participating practices are shown in Table 1.
Participants needed to be aged ≥18 years and able to provide consent, and be either staff or a 
patient at one of the general practice sites. Exclusion criteria were: cognitive impairment; severe 
psychiatric illness; use of immunologic agents; or pregnancy. There were no incentives provided to 
these practices to participate, although personal protective equipment (PPE) was supplied along with 
the equipment required to perform the study.
Two different serological POC kits for qualitative analysis of IgG and IgM directed against the 
receptor- binding domain of the SARS- CoV-2 spike protein were used: SARS- CoV-2 IgM/IgG Antibody 
Assay Colloidal Gold Complex test (Maccura Biotechnology Ltd, Chengdu, China) and the 2019- 
nCoV IgG/IgM Antibody Rapid test (Diagreat Biotechnologies Co Ltd, Beijing, China) with reported 
sensitivity and specificity for IgG of 71% and 98%,13 and 83% and 93%,33 respectively. All testing was 
performed in GP settings over a 4- week period from 15 June to 10 July 2020, in accordance with 
the manufacturers’ directions. Of note, this study is not intended as an assessment of the diagnostic 
performance of the lateral flow assays used (see Supplementary Table S1).
For the study period, all patients attending participating practices for routine care were informed 
about the study taking place and that they could participate if they so wished. Patients were informed 
that they would be blinded to the results of their POC test. Interested patients were provided with an 
information leaflet, and allowed time to consider whether or not they wanted to participate. Those who 
consented to participate then chose whether to supply a pinprick capillary blood sample or a single 
ethylenediaminetetraacetic acid (EDTA) blood sample via venepuncture; several drops of blood were 
applied to a small test cartridge along with a buffer solution for each of two separate test kits, and results 
read 15 minutes later.
Finally, a brief clinical history was taken (see Supplementary Box S1) and recorded on a standardised 
data collection sheet in order to estimate onset of relevant symptoms since the beginning of the pandemic, 
if any, and previous PCR testing for SARS- CoV-2 via nasopharyngeal swab. Evidence of previous PCR 
results were obtained directly from patient testimony, although in practice, owing to the involvement 
of GPs in referral for community- based testing, many tests could be verified on the practice electronic 
medical record.




lage, town, or city)a
Practice size (small, 
medium, or large)b




Positive POC tests, either 
type positive, n (%)
1 Village Small Clare 97 6 (6)
2 Town Medium Clare 29 3 (10)
3 Town Medium Clare 49 4 (8)
4 Village Small Clare 50 0 (0)
5 Town Large Clare 52 1 (2)
6 Village Small Clare 50 6 (12)
7 Town Medium Limerick 322 74 (23)
8 Village Small Limerick 50 1 (2)
9 Village Small Limerick 17 2 (12)
10 City Large Limerick 50 4 (8)
11 City Large Limerick 50 2 (4)
12 City Large Limerick 50 2 (4)
13 Village Medium Limerick 45 10 (22)
14 Town Medium Tipperary 27 2 (7)
15 Town Small Tipperary 33 1 (3)
aVillage (population <1500), town (population 1500–10 000), and city (population >10 000). bSmall (General Medical Services [GMS] list <1000), medium 
(GMS list 1000–2000), and large (GMS list >2000).
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For quality assurance, 20 randomly selected samples from a bank of previously collected serum 
samples (10 samples from 2007 to 2008 and 10 samples from 2017 to 2018) were also tested with 
both kits as part of this study. All 20 samples were found to be negative, and the test control markers 
reacted appropriately and as specified.
Seroprevalence was defined as the proportion of participants who had a positive result for the 
IgG band on the two test kits used in the study. As in similar studies internationally, owing to the 
differences in sensitivity and specificity of the IgM antibody, its shorter duration, and the heterogeneity 
of IgM results seen previously,18,19,34 seroprevalence results presented herein are based only on IgG 
antibodies.
In order to convert the observed positive and negative values of each test to a population level 
estimate of seroprevalence, the reported data on sensitivity and specificity were used for each test.13,33 
Of note, the probability an individual tests positive on a given test is the probability that they have 
true disease multiplied by the sensitivity of the test plus the probability that they do not have true 
disease multiplied by 1 — specificity of the test. Inverting this relationship allows estimation of true 
seroprevalence given the test results.
Since the estimated sensitivity and specificity of the tests are based on relatively small numbers,13,33 
this process was carried out using Monte Carlo estimation and 95% confidence intervals (CIs) are 
reported. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
checklist35 was followed during design of this study. Analyses were completed using R (version 4.0.5) 
and IBM SPSS Statistics (version 24.0).
Results
Practice recruitment
Fifteen practices were approached to participate in the study and all agreed to do so, with allocation 
of POC tests varying according to practice size and scope of practices to recruit during the 4- week 
study period (Table 1).
Participant recruitment and characteristics
From these practices, 971 participants (n = 799 patients, n = 172 staff) were recruited and tested 
using both POC test kits (Table 2). Venepuncture was favoured by 910 participants. The number of 
participants drawn from each practice was determined by the size of the practice and whatever was 
feasible for the practice to recruit in the 4 weeks of the study. The mean age of participants was 53.0 
years (standard deviation [SD] 17.2) with an age range of 18–97 years. Of the entire cohort, 60% were 
female, 82% were patients, and the remainder (18%) were healthcare staff with similar numbers of 
administration staff, nursing staff, doctors, and other healthcare staff across this group. With regard to 
previous testing, 139 (14%) had undergone prior PCR testing for SARS- CoV-2 and 33 of these (24%) 
had tested positive.
Regarding previous symptoms suggestive of SARS- CoV-2, 339 (35%) of all participants described 
such symptoms, of which the majority (57%) were 'moderate' in severity. Less than one- third (32%) of 
those patients with previous relevant symptoms had undergone a PCR test for SARS- CoV-2, and 17% 
of those who were seropositive were asymptomatic in the months preceding the testing.
Seroprevalence
Of the 971 participants, 967 had valid test results using the Maccura test kit and 918 using the 
Diagreat test kits, with 914 participants having valid test results for both test kits (see Table 3 for 
full results for both kits). One practice only used a single test kit (Maccura) instead of both on all 
participants resulting in reduced numbers for the Diagreat test. A control strip did not appear for a 
single participant for each test kit (99.9% performance for the control strip for each test kit) so both of 
these results were excluded from the final analysis.
Seroprevalence was estimated with greater precision by the Maccura test owing to the greater 
amount of performance data available13 on its sensitivity and specificity. Seroprevalence based on 
the Maccura test was estimated to be 12.6% (95% CI = 7.5% to 16.6%) in patients attending general 
practice and 11.1% (95% CI = 4.2% to 18.6%) in staff working in general practice. Administrative staff 
exhibited lowest seroprevalence at 2.5% (95% CI = 0.0% to 16.7%) and nursing staff the highest at 
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17.6% (95% CI = 5.9% to 33.8%). Seroprevalence was similar in males and females; was lowest in those 
aged ≥65 years; and increased in those who had previous symptoms suggestive of SARS- CoV-2 or 
who had undergone a PCR test for SARS- CoV-2.
Of the 339 (35%) participants who reported symptoms since the beginning of the pandemic, 83 
(24% of those reporting symptoms) demonstrated evidence of IgG to SARS- CoV-2.
For the 33 patients with previous PCR- confirmed COVID-19 infection, 27 (82% of previously 
infected individuals) showed serologic evidence of IgG to SARS- CoV-2 with one or both of the kits. 
For this subgroup, mean duration between their positive PCR test and the positive serology test 
for IgG was 83 days (95% CI = 77 to 89). Of note, 28 of the 33 PCR- positive patients reported 
symptoms of COVID-19 before previously testing positive for COVID-19, whereas the remaining five 
were asymptomatic prior to their positive PCR test..
For the six previously diagnosed patients who did not show evidence of IgG on either test kit, 
mean duration between their positive PCR test and the serology test was 77 days (95% CI = 44 to 
111). Five of these patients reported symptoms of COVID-19 before their positive PCR test.
Table 2 Baseline characteristics of all participants, including previous symptoms, PCR testing, and 
antibody detection
Participant charac-
teristics Total, n = 971
Previous symptoms sug-
gestive of SARS- CoV-2,
n = 339
Previous PCR naso-
pharyngeal swab for 
SARS- CoV-2,
n = 139
Either antibody test 
positive,
n = 118
Age, years Mean SD Mean SD Mean SD Mean SD
53.0 17.2 49.8 15.4 51.7 13.6 50.3 15.8
Median Range Median Range Median Range Median Range
55 18–97 51 18–88 53 20–84 54 18–80
Sex Patients, n Patients, % Patients, n Patients, % Patients, n Patients, % Patients, n Patients, %
Male 392 40 120 35 50 36 46 39
Female 579 60 219 65 89 64 72 61
Participant type
1. Patient 799 82 271 80 93 67 98 83
2. Healthcare staff 172 18 68 20 46 33 20 17
2.1 Administration 34 4 10 3 6 4 2 2
2.2 Nursing 51 5 24 7 16 12 8 7
2.3 Doctor 40 4 14 4 14 10 4 3
2.4 Other 
healthcare staff
47 5 20 6 10 7 6 5
History PCR and 
symptoms
Previous PCR test 
for SARS- CoV-2
139 14 108 32 139 100 43 36
  Positive PCR test 33 24 28 26 33 24 27 63
Previous symptoms 
suggestive of SARS- 
CoV-2
339 35 — — 108 78 83 70
Severity of 
symptoms
Mild 112 12 112 33 22 16 23 19
Moderate 193 20 193 57 70 50 52 44
Severe 34 4 34 10 16 12 8 7
PCR = polymerase chain reaction. SD = standard deviation.
O'Callaghan ME et al. BJGP Open 2021; DOI: 10.3399/BJGPO.2021.0038
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Relative performance of POC 
tests with PCR testing
Of the participants who had a valid Maccura 
test, 33 had previously tested positive on PCR 
for SARS- CoV-2 and 26 tested positive for IgG, 
demonstrating 79% (95% CI = 64% to 94%) 
positivity. For the Diagreat test, 32 had previously 
tested positive on PCR for SARS- CoV-2 and 25 
tested positive for IgG on the Diagreat test, 




Seroprevalence for SARS- CoV-2 IgG antibodies 
was 12.6% for patients attending general 
practice and 11.1% for practice staff. Nursing 
staff demonstrated the highest seroprevalence 
levels while administrative staff, presumably owing to relatively less direct patient contact, had lowest 
seroprevalence. Seroprevalence was similar across sex, was lowest in those aged ≥65 years, and was 
increased in those who had previous symptoms suggestive of COVID-19 or who had undergone a PCR 
test for COVID-19.
Notably, more than two- thirds of participants with previous symptoms suggestive of COVID-19 had 
not undergone a PCR test for COVID-19. This likely reflects the fact that there was limited availability of 
PCR tests, and thus more stringent criteria for testing in Ireland in the early stages of the pandemic.36
Results across practices varied from no detection to IgG detection in 23% of participants, presumably 
owing to considerable variability in COVID-19 geographic spread early in the pandemic. The vast 
majority of participants chose venepuncture to provide the blood sample for analysis, presumably 
owing to the fact that obtaining several drops of blood by capillary blood sampling would be more 
painful. Additionally, many of these patients were likely to be attending general practice that day for 
phlebotomy, and participation in the study did not mean any additional venepuncture.
While recognising not all those with PCR- confirmed COVID-19 infection will have produced IgG in 
response25,26 and IgG levels can wane,27 IgG antibodies were detected in 82% of participants with a 
confirmed prior COVID-19 infection, with a mean duration of nearly 3 months between diagnosis of 
infection and antibody detection.
Strengths and limitations
Key strengths of this study were the large number of patients from a reasonably wide selection of 
practices, which were recruited to the study with good representation across age and sex. Limitations 
include restriction of the study to the Midwest of Ireland and limited numbers of healthcare staff, 
meaning seroprevalence rates of the various staff categories had wide CIs. However, practices were 
purposefully selected to represent the entire region and different communities within the region, 
which is borne out by the differing seroprevalence rates recorded.
Patients and staff who had a history of COVID-19 infection or suggestive symptoms may have been 
more willing to participate in the study to assess their 'immunity' and thus further studies are needed 
to establish true prevalence of antibodies in GP staff and patients, and how this is changing over time.
An additional limitation arises from using a previous positive PCR result as a proxy for true SARS- 
CoV-2 infection in the seroprevalence analyses, as PCR tests have their own fallibilities. Similarly, 
any POC testing kit has inherent limitations, and IgG levels to SARS- CoV-2 are also known to drop 
in some patients over time.23,27 However, even with these limitations, the analyses reveal plausible 
seroconversion rates that help describe the known previous clinical history of many people in the 
study.
Table 4 Relationship between Diagreat and 
Maccura IgG test results and previously positive 




positive, n Total, n
Diagreat Test
PCR negative 89 13 102
PCR positive 7 25 32
Total 96 38 134
Maccura Test
PCR negative 92 13 105
PCR positive 7 26 33
Total 99 39 138
IgG = immunoglobulin G. IgM = immunoglobulin M. 
PCR = polymerase chain reaction.
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Finally, some individuals do not develop a detectable antibody response for a variety of reasons, 
such as T- cell immune response, and these prior infections will not be detected in a seroprevalence 
study.24,28,37,38
Comparison with existing literature
Healthcare workers have been at higher risk of COVID-19 infection than the general population owing 
to exposure to infected patients and crowded enclosed environments.39–41 They have been shown to 
be more than 10 times more likely to contract COVID-19 compared with the general public,31 and 
evidence suggests hospital staff without direct patient contact are also at higher risk of infection.32
From the patient perspective, those with chronic conditions spend more time in general practice 
and other healthcare settings as they often need closer monitoring and more frequent treatment.42 It 
is plausible that such patients with increased medical need continued to visit many healthcare settings 
during the pandemic, thereby increasing their risk of contracting COVID-19 within these high- risk 
environments.
At the same time as the study was carried out, a national seroprevalence study (SCOPI)43 was 
undertaken by the Irish Health Protection Surveillance Centre (HPSC). This involved cross- sectional 
sampling of people living in two areas in Ireland: one with a high incidence of confirmed COVID-19 
cases (Dublin); and the other with a lower incidence of confirmed COVID-19 cases (Sligo). The findings 
of the study were then extrapolated to estimate an overall prevalence for Ireland of 1.7%,43 giving 
the participants in the present study a rate of infection more than seven times the national average 
at the time.
More recently, a large study of 5700 healthcare workers in two hospitals situated in areas of high 
COVID-19 incidence (Dublin) and lower incidence (Galway) has shown prevalence of SARS- CoV-2 IgG 
antibodies in 15.0% and 4.1% of participants, respectively.44
To the authors’ knowledge, there are no seroprevalence data from community healthcare settings 
in Ireland available, and indeed little internationally, but data are available from Spain where a 
seroprevalence rate of 5.5%–5.9% has been demonstrated.45,46 The present study makes a valuable 
contribution to the knowledge regarding potential levels of circulating SARS- CoV-2 in such settings in 
Ireland and the methodology may assist future similar studies in Irish general practice.
As studies with longer follow- up emerge,21–28 persistence of antibodies in a majority of infected 
individuals for a reasonable length of time may be welcome news for vaccination efforts and indeed for 
those patients who have overcome COVID-19 infection. However, what IgG levels mean for protection 
from subsequent infection remains to be seen.
Implications for research and practice
Patients and healthcare staff in general practice in Ireland demonstrated higher evidence of COVID-19 
infection than seen in the general public nationally and similar to rates seen in hospital- based 
healthcare workers in areas of high- disease activity.
Venepuncture was chosen over capillary blood sampling by most participants and routine 
venepuncture for other reasons in general practice may provide opportunities for future seroprevalence 
studies.
The number of individuals with detectable levels of IgG, if taken as a proxy for some degree of 
immunity, while greater than the national average, was far below that of a reasonable population- 
level 'herd immunity' threshold.38 This implies COVID-19 has not swept silently through community 
settings, and highlights the importance of continued compliance with simple public health measures 
until vaccination efforts mature and more is learnt about their effect on this pandemic.
Comparison of positive PCR results and the POC test kits demonstrates how use of distinct testing 
methods on the same participants can offer some quality assurance and compensation for each 
test’s inherent fallibilities and differing sensitivities. While POC tests used in the study may not be 
conclusive about immunity to any or all strains of SARS- CoV-2, it seems prudent to continue study of 
this important aspect of the immune system’s response to this novel virus.
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